Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

ABSTRACT: Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.

DISEASE(S): Neuroendocrine Tumors,Sclc,Pancreatic Adenocarcinoma,Carcinoma,Sarcoma,Malignant Solid Tumor,Tumori Solidi Avanzati Selezionati,Glioblastoma,Advanced Solid Tumors,Mesothelioma,Endometrial Neoplasms,Neoplasms,Colorectal Carcinoma,Soft Tissue Sarcoma (excluding Gist),Epithelial Ovarian Carcinoma,Gastric Carcinoma,Carcinoma, Ovarian Epithelial,Colorectal Neoplasms,Gastroenteropancreatic Neuroendocrine Tumor,Stomach Neoplasms,Endometrial Carcinoma,Selected Advanced Solid Tumors,Cancer

PROVIDER: 2202796 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR